% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Flaskamp:281188,
      author       = {Flaskamp, Lavinia and Prechtl, Monica and Scheck,
                      Annkathrin and Hu, Wenbo and Ried, Christine and Kislinger,
                      Georg and Simons, Mikael and Krug, Anne B. and Kranich, Jan
                      and Brocker, Thomas},
      title        = {{A}ssessing {E}xtracellular {V}esicle {T}urnover {I}n
                      {V}ivo {U}sing {H}ighly {S}ensitive
                      {P}hosphatidylserine‐{B}inding {R}eagents},
      journal      = {Advanced science},
      volume       = {Advance online publication},
      issn         = {2198-3844},
      address      = {Weinheim},
      publisher    = {Wiley-VCH},
      reportid     = {DZNE-2025-01089},
      pages        = {e07624},
      year         = {2025},
      abstract     = {Extracellular vesicles (EVs) are emerging as crucial
                      players in cell communication and hold great promise as
                      biomarkers and therapeutic tools. However, their diversity
                      makes it challenging to detect, classify, and utilize them
                      effectively, which limits their clinical applicability. A
                      key challenge is the lack of reliable markers to identify
                      EVs consistently. In this study, a novel high-affinity
                      phosphatidylserine (PS)-binding reagent is introduced for EV
                      analysis. PS is known as a marker of apoptotic cells and
                      activated platelets, but its presence on EVs is debated due
                      to variations in lipid composition. By comparing multiple
                      PS-binding reagents, including MFG-E8 derivatives and
                      Annexin V, it is demonstrated that $≈90\%$ of EVs in human
                      and mouse blood carry PS. Using the optimized reagent, the
                      first in vivo insights into EV turnover are provided,
                      showing that PS+ EVs in mouse blood are rapidly cleared
                      $(≈50\%$ within 30 min) but persist on immune cells in the
                      spleen. This discovery increases the potential of EVs as
                      disease biomarkers and therapeutic targets by improving EV
                      detection and isolation as well as opening the door for
                      standardized quantification and diagnostic monitoring.},
      cin          = {AG Simons},
      ddc          = {624},
      cid          = {I:(DE-2719)1110008},
      pnm          = {351 - Brain Function (POF4-351)},
      pid          = {G:(DE-HGF)POF4-351},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:40817753},
      doi          = {10.1002/advs.202507624},
      url          = {https://pub.dzne.de/record/281188},
}